A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516869-36-00

Acronym

EXS73565-001

Enrollment

Registered

2025-01-23

Start date

2025-02-17

Completion date

Unknown

Last updated

2026-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), including RT (Richter’s Transformation) from CLL, mantle-cell lymphoma (MCL), marginal zone lymphoma (MZL), Relapsed or refractory B-cell malignancies: chronic lymphocytic leukemia (CLL)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Spain

Outcome results